Skip to main content
Premium Trial:

Request an Annual Quote

Amersham and Bayer to Develop, Commercialize HIV Assays; FDA OK Sought

NEW YORK, Feb. 16 (GenomeWeb News) - Amersham and Bayer's diagnostics division plan to co-develop assays and instrumentation for sequencing HIV and other infectious disease-causing pathogens, the companies said today.

 

Terms of the exclusive partnership call for Amersham to supply a modified version of its existing MegaBACE gene sequencer, and for Bayer to develop sequencing assay applications for the tool. Bayer will also buy Amersham's reagents and other consumables for these and "future assays," the companies said.

 

Amersham and Bayer plan to seek USregulatory approval for the instrument and assays. It was not immediately clear when the companies expect to commercialize the instrument or the assays.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.